2. Signaling Pathways
  3. Anti-infection
  4. SARS-CoV

SARS-CoV

SARS coronavirus

SARS-CoV

Related Products

PDF 0.94 MB

SARS-CoV is the coronavirus (CoV) that causes severe acute respiratory syndrome (SARS). CoVs are enveloped viruses with a positive-sense, single-stranded RNA and can cause health-threatening outbreaks by targeting human respiratory system, including not only SARS, but also Middle East respiratory syndrome (MERS) and SARS-CoV-2 (the cause of COVID-19).

CoVs have four main structural proteins: spike(S), membrane (M), envelope (E), and nucleocapsid (N) proteins. An S protein mediates the CoV entry into host cells by attaching to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), followed by fusion between virus and host cell membranes. Genome replication and subgenomic RNA transcription after entry carry on with the participation of many nonstructural proteins such as Mpro (main protease or 3CLpro), PLpro (papain-like protease) and RdRp (RNA-dependent RNA polymerase). Then the structural proteins are translated, assembled into mature virions, and released via vesicles by exocytosis. It is worth mentioning that a protease called TMPRSS2 (transmembrane protease, serine 2) play important roles throughout the whole life of CoVs (such as attachment, assembling and release) by cleaving S protein. All the proteins and subcellular structures participated in the life cycle of CoVs are promising targets for treatment of disease caused by CoVs.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-143216A
    Ensitrelvir fumarate
    		Inhibitor 99.99%
    Ensitrelvir (S-217622) fumarate is the first orally active non-covalent, non-peptidic, SARS-CoV-2 3CL protease inhibitor (IC50=13 nM).
    Ensitrelvir fumarate
  • HY-120852
    JG26
    		Inhibitor 98.14%
    JG26 is an ADAM inhibitor with IC50 values of 12 nM, 1.9 nM, and 150 nM for ADAM8, ADAM17, and ADAM10, respectively. JG26 inhibits MMP-12 with an IC50 value of 9.4 nM. JG26 inhibits AngII (HY-13948)-induced EGFR transactivation and ERK activation. JG26 increases the expression of ACE2, inhibits the cleavage of CD23, reduces the infection of SARS-CoV-2. JG26 inhibits colorectal cancer metastasis. JG26 can be used for research on Hodgkin lymphoma and vascular diseases.
    JG26
  • HY-135867E
    NHC-triphosphate tetraammonium
    		Inhibitor
    NHC-triphosphate tetraammonium is an active phosphorylated intracellular metabolite of β-d-N4-Hydroxycytidine (NHC) (HY-125033) as a triphosphate form. NHC-triphosphate tetraammonium is a weak alternative substrate for the viral polymerase and can be incorporated into HCV replicon RNA.
    NHC-triphosphate tetraammonium
  • HY-N0539
    Calceolarioside B
    		Inhibitor 99.93%
    Calceolarioside B is a phenylethanoid glycoside. Calceolarioside B can be isolated from the leaves of Akebia quinata. Calceolarioside B inhibits RLAR activity with an IC50 value of 23.99 μM. Calceolarioside B inhibits the entry of Omicron BA.2 into host cells. Calceolarioside B reduces IL-6 levels. Calceolarioside B has immunomodulatory activity. Calceolarioside B has anticancer activity against human hormone-independent prostate cancer.
    Calceolarioside B
  • HY-P99344
    Bamlanivimab
    		Inhibitor 99.97%
    Bamlanivimab (Anti-Human SARS-CoV-2) is the first COVID-19 monoclonal antibody (mAb) to be granted Emergency Use Authorization (EUA) in November 2020 by the U.S. Food and agent Administration (FDA). However, Bamlanivimab is withdrawn in April 2021 following the rise of SARS-CoV-2 virus variants resistant to Bamlanivimab.
    Bamlanivimab
  • HY-P99556
    Tixagevimab
    		Inhibitor ≥99.0%
    Tixagevimab (AZD8895) is a human monoclonal antibody that targets the SARS-CoV-2 receptor binding domain (RBD). It exhibits neutralizing activity against SARS-CoV-2 by binding to the RBD and the S-glycoprotein ectodomain and blocking S-glycoprotein-mediated binding to the receptor.
    Tixagevimab
  • HY-17589R
    Chloroquine phosphate (Standard)
    		Inhibitor
    Chloroquine (phosphate) (Standard) is the analytical standard of Chloroquine (phosphate). This product is intended for research and analytical applications. Chloroquine phosphate is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine phosphate is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine phosphate is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
    Chloroquine phosphate (Standard)
  • HY-N0713
    Diosmetin-7-O-β-D-glucopyranoside
    		Inhibitor 99.61%
    Diosmetin-7-O-β-D-glucopyranoside is a natural product that can be isolated from the flowers of Chrysanthemum morifolium. Diosmetin-7-O-β-D-glucopyranoside has potent antiviral and anti-inflammatory activities against SARS-CoV-2 both in vitro (IC50 = 0.74 μM) and in vivo. Diosmetin-7-O-β-D-glucopyranoside has significant anti-thrombotic activity when combined with Pae and 5-HMF at a ratio of 3:4:3 in a zebrafish model.
    Diosmetin-7-O-β-D-glucopyranoside
  • HY-Y1885
    Tetrasodium pyrophosphate
    		99.60%
    Tetrasodium pyrophosphate is a chelating that can bind calcium and help improve olfaction. Tetrasodium pyrophosphate is an antimicrobial agent that can reduce microbial colonization. Tetrasodium pyrophosphate is a biological material that is widely used in life science research. Tetrasodium pyrophosphate can be studied in research for alleviating symptoms post COVID-19.
    Tetrasodium pyrophosphate
  • HY-N1951
    Miltirone
    		Inhibitor 99.74%
    Miltirone is an orally active natural compound found in the root of Salvia miltiorrhiza. Miltirone is a central benzodiazepine receptor partial agonist, with an IC50 of 0.3 μM. Miltirone induces ROS - and-p53 dependent apoptosis. Miltirone inhibits carboxylesterase 2 (CES2; Ki = 0.04 μM) and SARS-CoV main protease (Mpro).
    Miltirone
  • HY-17589B
    Chloroquine dihydrochloride
    		Inhibitor 99.61%
    Chloroquine dihydrochloride is an antimalarial and anti-inflammatory agent widely used to treat malaria and rheumatoid arthritis. Chloroquine dihydrochloride is an autophagy and toll-like receptors (TLRs) inhibitor. Chloroquine dihydrochloride is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC50=1.13 μM).
    Chloroquine dihydrochloride
  • HY-14904
    Umifenovir
    		Inhibitor 98.00%
    Umifenovir is a potent, orally active broad-spectrum antiviral agent with activity against a number of enveloped and non-enveloped viruses. Umifenovir is used as an anti-influenza virus agent. Umifenovir could effectively inhibit the fusion of virus with host cells. Umifenovir is an efficient inhibitor of SARS-CoV-2 in vitro. Umifenovir shows anti-inflammatory activity.
    Umifenovir
  • HY-153228
    Pomotrelvir
    		Inhibitor
    Pomotrelvir is a selective, competitive, orally active covalent inhibitor of the SARS-CoV-2 main protease (Mpro), with an IC50 of 24 nM for wild-type SARS-CoV-2 Mpro. Pomotrelvir inhibits viral polyprotein processing, thereby preventing viral replication. Pomotrelvir has shown broad antiviral activity against multiple SARS-CoV-2 variants (including Omicron) in cell-based experiments, and has an additive effect when combined with nucleoside analogs that target viral RNA synthesis. Pomotrelvir is primarily used for the research and development of COVID-19 antiviral drugs, especially for infections caused by SARS-CoV-2 and its variants.
    Pomotrelvir
  • HY-137048
    PF-00835231
    		Inhibitor 99.31%
    PF-00835231 is a CoV-2 cysteine 3C-like protease (3CLpro) inhibitor, with IC50s of 0.27 nM and 4 nM for SARS CoV-2 and SARS CoV-1 3CLpro, respectively. PF-00835231 is developed for the research of anti-SARS-CoV-2/COVID-19. PF-00835231 can inhibit cell infections and also suppress infections in animal models.
    PF-00835231
  • HY-18337
    IOWH-032
    		Modulator 99.63%
    IOWH-032 is a a synthetic anti-secretory molecule, is a potent CFTR inhibitor with an IC50 value of 8 μM. IOWH-032 also is a anti-diarrheal agent.
    IOWH-032
  • HY-18649
    Galidesivir hydrochloride
    		Inhibitor 99.89%
    Galidesivir (BCX4430) hydrochloride, an adenosine analog and a direct-acting antiviral agent, disrupts viral RNA-dependent RNA polymerase (RdRp) activity. Galidesivir hydrochloride is active in vitro against many RNA viral pathogens, including the filoviruses and emerging infectious agents such as MERS-CoV, SARS-CoV, and SARS-CoV-2. Galidesivir hydrochloride inhibits some negative-sense RNA viruses with EC50s ranging from ~3 to ~68 μM.
    Galidesivir hydrochloride
  • HY-12648A
    FASN-IN-4 tosylate
    		Inhibitor 98.55%
    FASN-IN-4 tosylate is a potent inhibitor of fatty acid synthase (FASN) with an IC50 of 10 nM (WO2012064642A1, compound 29). FASN-IN-4 tosylate also inhibits SARS-CoV-2 with an EC50 of 18.6?nM.
    FASN-IN-4 tosylate
  • HY-137958A
    Bemnifosbuvir
    		Inhibitor 99.00%
    Bemnifosbuvir (AT-511) is a potent and orally active HCV viral replication inhibitor. Bemnifosbuvir is highly effective in the control of SARS-CoV-2 (COVID-19) infection in vitro (EC90=0.47 μM). Bemnifosbuvir has pangenotypic antiviral activity.
    Bemnifosbuvir
  • HY-15298B
    Grazoprevir hydrate
    		Inhibitor 99.99%
    Grazoprevir hydrate (MK-5172 hydrate) is a selective inhibitor of Hepatitis C virus NS3/4a protease with broad activity across genotypes and resistant variants, with Kis of 0.01 nM (gt1b), 0.01 nM (gt1a), 0.08 nM (gt2a), 0.15 nM (gt2b), 0.90 nM (gt3a), respectively. Grazoprevir hydrate inhibits SARS-CoV-2 3CLpro activity.
    Grazoprevir hydrate
  • HY-131611
    6-Azuridine
    		Inhibitor 99.83%
    6-Azuridine (6-Azauridine) is an orally active purine nucleoside analogue. 6-Azuridine activates autophagic flux, induces Apoptosis that depends on AMPK and p53. 6-Azuridine exhibit both antitumor and antiviral activities.
    6-Azuridine
Cat. No. Product Name / Synonyms Species Source